- Home
- LGTY vs GHRS Comparison
LGTY vs GHRS Comparison
Compare LGTY & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGTY
- GHRS
- Stock Information
- Founded
- LGTY 1970
- GHRS 2018
- Country
- LGTY United States
- GHRS Ireland
- Employees
- LGTY N/A
- GHRS 49
- Industry
- LGTY
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- LGTY
- GHRS Health Care
- Exchange
- LGTY NYSE
- GHRS Nasdaq
- Market Cap
- LGTY 411.9M
- GHRS 356.4M
- IPO Year
- LGTY N/A
- GHRS 2021
- Fundamental
- Price
- LGTY $10.82
- GHRS $6.85
- Analyst Decision
- LGTY
- GHRS Strong Buy
- Analyst Count
- LGTY 0
- GHRS 3
- Target Price
- LGTY N/A
- GHRS $35.67
- AVG Volume (30 Days)
- LGTY 376.7K
- GHRS 58.0K
- Earning Date
- LGTY 02-20-2025
- GHRS 11-14-2024
- Dividend Yield
- LGTY 4.07%
- GHRS N/A
- EPS Growth
- LGTY N/A
- GHRS N/A
- EPS
- LGTY 0.30
- GHRS N/A
- Revenue
- LGTY $102,402,000.00
- GHRS N/A
- Revenue This Year
- LGTY N/A
- GHRS N/A
- Revenue Next Year
- LGTY N/A
- GHRS N/A
- P/E Ratio
- LGTY $35.95
- GHRS N/A
- Revenue Growth
- LGTY N/A
- GHRS N/A
- 52 Week Low
- LGTY $8.41
- GHRS $5.08
- 52 Week High
- LGTY $12.30
- GHRS $14.99
- Technical
- Relative Strength Index (RSI)
- LGTY N/A
- GHRS 35.35
- Support Level
- LGTY N/A
- GHRS $7.20
- Resistance Level
- LGTY N/A
- GHRS $8.91
- Average True Range (ATR)
- LGTY 0.00
- GHRS 0.86
- MACD
- LGTY 0.00
- GHRS -0.18
- Stochastic Oscillator
- LGTY 0.00
- GHRS 3.96
About LGTY LOGILITY SUPPLY CHAIN SOLUTIONS INC
Logility Supply Chain Solutions Inc develops enterprise management and supply chain-related software and services. Its Services include Scenario Planning Products, Demand Planning InventoryAI+, Supply, Deployment, Supply Chain Data Management, and Supply Chain Design. The group provides services to various industries such as Food and Beverage Consumer Packaged Goods, Process Manufacturing, Industrial Manufacturing, Chemicals, and others.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.